3 US Value Stocks Built For Higher Rates

Inflation running hotter than forecasts, a firmly hawkish Fed and a jump in bond yields have pushed many investors to rethink where they feel comfortable putting new money to work. Higher borrowing costs can punish stretched balance sheets, yet they can also reward cash rich, profitable businesses that do not lean heavily on debt. This article walks through three large cap quality value stocks from our screener that appear closely tied to this new rate reality.

The three stocks that follow are just a sample set. The full screen surfaced 31 more large cap value candidates with similarly detailed stories that do not fit into a short article. To go deeper, analyze and identify potential high conviction ideas directly through the U.S. Large-Cap Quality Value Stocks (Profitable, Low-Leverage Companies) screener.

Abbott Laboratories (ABT)

Abbott Laboratories appears well suited to this quality value screen, with a long history in essential healthcare products and a reputation for resilient cash generation that the analyst consensus Narrative on Simply Wall St links to a maturing medical technology and diagnostics pipeline.

Abbott Laboratories is a diversified healthcare group spanning generic drugs, diagnostics, nutrition and medical devices. Most of its approximately US$48.2b in segment sales comes from Medical Devices at about US$22.9b, followed by Diagnostics at US$11.0b, Nutrition at US$8.4b and Established Pharmaceuticals at US$5.9b, and the business carries a market value around US$190.4b.

Broader adoption of continuous glucose monitoring, including expected Centers for Medicare and Medicaid Services coverage for non insulin users that could open access to about 10 million additional Medicare beneficiaries, together with the planned U.S. launch of Libre Duo and further system integrations, can support higher CGM sensor volumes and contribute to top line growth.

The key question is how one unresolved pressure on profitability develops if conditions remain challenging for longer than this consensus path assumes.

If that pressure point keeps you curious, the full narrative for Abbott Laboratories explains how Abbott Laboratories could balance CGM momentum with potential profitability risks that may be masking beneath the surface.

General Dynamics (GD)

General Dynamics fits this large cap quality value screen as a major U.S. aerospace and defense contractor with disciplined use of debt, combining US$18.8b from Marine Systems, US$14.1b from Aerospace, US$14.1b from Technologies and US$9.5b from Combat Systems, and a market value around US$95.5b.

CentryResearch, a Simply Wall St Community investor who wrote the Narrative, argues that what really matters for General Dynamics is the scale and duration of its submarine work with the U.S. Navy.

An order that waited three years. In 2023, Congress gave the Navy permission to buy up to 13 attack submarines in one large deal. That is the kind of order that keeps a shipyard busy for years.

The real swing factor now is how one less obvious cost and execution pressure shapes the profits investors ultimately see from that backlog.

That hidden pressure point is exactly where the full narrative for General Dynamics shows how General Dynamics' submarine backlog, capital needs and execution risk could be quietly reshaping long term cash generation.

L3Harris Technologies (LHX)

L3Harris Technologies is a large cap defense and mission critical communications provider in the U.S. Large Cap Quality Value Stocks screen, with a market value near US$48.4b and revenue reported under segment adjustments of about US$23.3b.

L3Harris Technologies supplies mission critical radios, satellite systems and missile technologies for government and commercial customers. This fits the screener’s focus on profitable, lower beta industrials that rely less on heavy borrowing.

The thing that stands out is that we're not just seeing a defence spending story anymore. We're seeing execution.

What matters from here is how one emerging pressure on contract economics shapes the cash generation story that investors are building into L3Harris.

When contract economics start to quietly shift, the full narrative for L3Harris Technologies shows how the execution story at L3Harris Technologies could be accelerating well beyond headline defence spending worries.

Seeking Fresh Alternatives Before They Fly

Fresh ideas move first. By the time momentum hits headlines, the cleanest entries can be gone. Scan curated shortlists that are under the radar for now and look for opportunities early.

• Target reliable income streams with companies filtered for strong payouts and staying power using the 6 dividend fortresses before yields are repriced.
• Spot early AI momentum where profits already support the story by tracking the 42 profitable AI stocks that aren't just burning cash while these operators are still quietly compounding.
• Consider positioning for a potential materials breakout with producers surfaced through the 16 top copper producer stocks before supply and demand pressures are fully reflected in prices.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com